Ara
Toplam kayıt 4, listelenen: 1-4
How to perform and manage low-dose and slow/ultra-slow tissue type plasminogen activator infusion regimens in patients with prosthetic valve thrombosis
(Springer New York LLC, 2018)
Over the last two decades, thrombolytic therapy (TT) has become an alternative to surgery as a first-line therapy in patients with thrombosed mechanical valves [1, 2, 3]. In TROIA Trial, low dose (25 mg)—slow infusion (6 ...
What is the importance of real-time three dimensional transesophageal echocardiography and time in therapeutic range in patients with prosthetic valve thrombosis?
(Springer New York LLC, 2018)
We have recently read with great interest the article reported by Cınar et al. which was published in the last issue of the Journal of Thrombosis and Thrombolysis [1]. We appreciate the authors for their report describing ...
Is high thromboembolic risk not really associated with low time in therapeutic range in patients with prosthetic heart valves?
(Elsevier Ireland Ltd, 2019)
Dear Editor,
We have recently read with great interest the article reported by Poli et al. which was published in the last issue of International Journal of Cardiology [1]. We appreciate the authors for valuable contribution ...
Pregnancy in patients with prosthetic heart valve: ongoing challenges
(SAGE Publications Ltd, 2019)
[No abstract available]